arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Phathom Pharmaceuticals, Inc.

PHAT
$5.07 ▼ -0.62 (-10.90%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
54
Health
Fair
Neutral
auto_awesome

Analytical Summary

Phathom Pharmaceuticals, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $430.4M
Dividend Yield —
Revenue Growth 71.1% ↘
Op. Margin -0.1% ↗
ROIC 0.0% ↘
FCF / Share $0.02 ↗
Trailing P/E —
Price / Book —
FCF Yield 0.4%
Debt / Equity -0.48
info Valuation on last close. End-of-day price, Nov 5, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$84.72M
↑ +71.1% —
Net Income Profit after all expenses
$-30.37M
↑ +67.8% —
Operating Margin Operating profit as % of sales
-0.1%
↑ +98.1% 2th
FCF / Share Free cash flow per share
$0.02
↑ +186.4% —
Long-Term Debt Long-term obligations
$165.54M
↑ +0.6% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
2
Returns
97
Financial Health ↑
67
Cash Quality ↓
51

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 9 years · 36 quarters